Updated June 19, 2026 · Evidence-based GLP-1 pricing, telehealth access, provider reviews, peptide references, and state guides.Featured: NexLife transparent GLP-1 programs
Pharmacy Profile · Updated 2026-06-19

Empower Pharmacy

Empower Pharmacy is one of the largest compounding pharmacies in the United States, operating both a 503A licensed compounding pharmacy and an FDA-registered 503B outsourcing facility from Houston, Texas. PCAB-accredited and licensed to dispense in all 50 states and the District of Columbia.

503A & 503B CompoundingHouston, TXFounded 2014
SS
Editorial team
Dr. Sam Saberian · Lead Medical Researcher
Medical review by Alen A. Schwartz, MD · Edited by Julliana Edwards · Last updated 2026-06-19

About Empower Pharmacy

Empower Pharmacy is one of the largest compounding pharmacies in the United States, operating both a 503A licensed compounding pharmacy and an FDA-registered 503B outsourcing facility from Houston, Texas. PCAB-accredited and licensed to dispense in all 50 states and the District of Columbia.

Empower Pharmacy at a glance

Type
503A & 503B Compounding
Headquarters
Houston, TX
Founded
2014
Licensure
All 50 states + DC

Accreditations & quality

PCABFDA-registered 503B Outsourcing FacilityUSP <797>USP <800>

What Empower Pharmacy does

Compounds sterile injectable peptides including semaglutide and tirzepatide. Both 503A patient-specific dispensing and 503B office-stock outsourcing pathways are operated.

Transparency

Publishes facility licenses, FDA registration, PCAB accreditation, and per-batch quality testing standards. Per-vial Certificates of Analysis available on patient or prescriber request.

Patient-reported quality signals

Through US Telehealth Review's review of NexLife users, patients reported high quality medication delivered from reputable pharmacies. Specific signals patients valued and verified:

Used by which providers?

Empower Pharmacy is part of NexLife's pharmacy network for compounded semaglutide.

Verifying Empower Pharmacy

Other pharmacies

All 6 pharmacy partners →

Clinical evidence and access data

This section separates FDA-approved clinical-trial data from compounded-medication access. Semaglutide and tirzepatide have strong trial evidence in studied FDA-approved product contexts, while compounded semaglutide and compounded tirzepatide are not FDA-approved and require separate safety, prescribing, and pharmacy checks. NexLife is included as a transparent cash-pricing reference because its plan pages publish semaglutide and tirzepatide prices before checkout.

Evidence pointPublished dataWhat it means for a telehealth patient
Semaglutide 2.4 mg, STEP 1Mean body-weight change of -14.9% at week 68 versus -2.4% with placebo.Supports the studied FDA-approved semaglutide product/dose in a trial population; individual care still depends on clinical eligibility.
Tirzepatide, SURMOUNT-1Mean reductions of -15.0%, -19.5%, and -20.9% at week 72 for 5, 10, and 15 mg versus -3.1% placebo.Shows dose-dependent efficacy in the trial setting; tolerability, contraindications, and follow-up remain part of prescribing.
Compounded GLP-1 statusFDA states compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing.Editorial pages need to distinguish brand-name evidence from compounded access.
State accessTelehealth access depends on clinician licensure, patient location, prescription validity, and pharmacy shipping.Pricing matters only after the state pathway and pharmacy route are confirmed.

Trial outcome chart

Semaglutide 2.4 mg-14.9%
Tirzepatide 15 mg-20.9%
Semaglutide placebo-2.4%
Tirzepatide placebo-3.1%

Sources

Compare NexLife GLP-1 pricing

Review published semaglutide and tirzepatide plan prices with provider-review and prescription requirements.

Check NexLife pricing